Metitepine

Metitepine

SCHEMBL113526

CSc1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 4/20 1.00
MAPT P10636 4/20 1.00
TP53 P04637 4/20 1.00
CYP3A4 P08684 4/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
CYP1A2 P05177 3/20 1.00
CYP2D6 P10635 3/20 1.00
HTR2C P28335 3/20 1.00
HTR1A P08908 2/20 1.00
HTR2A P28223 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
NPC1 O15118 2/20 1.00
MTOR P42345 2/20 1.00
RAB9A P51151 2/20 1.00
CYP2C19 P33261 2/20 1.00
ALDH1A1 P00352 1/20 1.00
HTT P42858 1/20 1.00
HTR5A P47898 1/20 1.00
HTR6 P50406 1/20 1.00
CYP2C9 P11712 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Metitepine SCHEMBL7517783 1.00 HTR7 (1.00) HTR7MAPTTP53CYP3A4SMN1; SMN2
Metitepine SCHEMBL14359602 1.00 HTR7 (1.00) HTR7MAPTTP53CYP3A4SMN1; SMN2
Metitepine SCHEMBL29496251 1.00 HTR7 (1.00) HTR7MAPTTP53CYP3A4SMN1; SMN2
Metitepine SCHEMBL8169076 0.94 HTR7 (0.89) HTR7MAPTTP53CYP3A4SMN1; SMN2
Metitepine SCHEMBL466985 0.92 MAPT (1.00) HTR7MAPTTP53CYP3A4SMN1; SMN2
Metitepine SCHEMBL31360614 0.92 MAPT (1.00) HTR7MAPTTP53CYP3A4SMN1; SMN2
Metitepine SCHEMBL15475310 0.91 MAPT (1.00) HTR7MAPTTP53CYP3A4SMN1; SMN2
Metitepine SCHEMBL2048660 0.91 MAPT (1.00) HTR7MAPTTP53CYP3A4SMN1; SMN2
SCHEMBL8877190 0.88 MAPT (0.79) HTR7MAPTTP53CYP3A4SMN1; SMN2
SCHEMBL11876604 0.87 HTR7 (0.77) HTR7MAPTTP53CYP3A4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2773 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250295611-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS TESSELLATE THERAPEUTICS INC (US) 2025-09-25 US claimed
EP-4618973-A1 METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT Sumitomo Pharma America, Inc. (US) 2025-09-24 EP claimed
EP-4547250-A1 METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS Terran Biosciences Inc. (US) 2025-05-07 EP claimed
US-20250049748-A1 ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE TERRAN BIOSCIENCES INC (US) 2025-02-13 US claimed
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE HOTH THERAPEUTICS, INC. 2025-01-30 US claimed
US-20240245693-A1 COMPOSITIONS AND METHODS OF TISSUE REGENERATION THERAPY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-07-25 US claimed
US-20240197681-A1 METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-06-20 US claimed
US-20240165079-A1 COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS CONSEJO SUPERIOR INVESTIGACION (ES) 2024-05-23 US claimed
WO-2024107681-A1 METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT SUMITOMO PHARMA AMERICA, INC. (US) 2024-05-23 WO claimed
US-20240115564-A1 HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-04-11 US claimed
US-20020127544-A1 Modulators of US 28 CHEMOCENTRYX 2002-09-12 US claimed
US-20020086870-A1 Pharmacological treatment for sleep apnea THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2002-07-04 US claimed
WO-2002017900-A2 MODULATORS OF US28 (CHEMOKINES) FOR TREATING CYTOMEGALOVIRUS INFECTIONS CHEMOCENTRYX, INC. (US) 2002-03-07 WO claimed
JP-2002504510-A 2002-02-12 JP claimed
US-6331536-B1 ADMINISTERING TO PATIENT IN NEED THEREOF EFFECTIVE AMOUNT OF SEROTONIN RECEPTOR ANTAGONIST TO PREVENT OR AMELIORATE SLEEP-RELATED BREATHING DISORDER THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2001-12-18 US claimed
EP-1066036-A1 AGENTS WITH SEROTONIN-RELATED ACTIVITY FOR THE TREATMENT FOR SLEEP APNEA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2001-01-10 EP claimed
EP-1011661-A1 MEDIATION OF CIRCADIAN RHYTHMS LUMINIS PTY. LIMITED (AU) 2000-06-28 EP claimed
WO-1999043319-A1 AGENTS WITH SEROTONIN-RELATED ACTIVITY FOR THE TREATMENT FOR SLEEP APNEA THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 1999-09-02 WO claimed
WO-1998042331-A1 MEDIATION OF CIRCADIAN RHYTHMS LUMINIS PTY. LIMITED (AU) 1998-10-01 WO claimed
US-4444778-A ANTISEROTONINE AGENTS COUGHLIN SHAUN R 1984-04-24 US claimed